A vs AMD Stock Comparison

Scores Breakdown

Metric	A	AMD
📈 Growth	18/30	28/30
💰 Profitability	16/20	16/20
🏦 Financial Health	7/20	18/20
💵 Valuation	9/20	15/20
⚠️ Risk (lower is better)	7/10	7/10
Overall Score	53/100	80/100

Side-by-Side Summaries

A Analysis	AMD Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from roughly $7.44B to about $10.25B, a sustained upshift with a brief mid-period pause. Net Income climbed from about $0.264B to $1.383B, with quarterly oscillations but a clear uptrend (peaks in 2025 Q4 and 2026 Q1). 💰 Margins & Cash Flow Gross margins held near 50-54%, with quarterly gross profit around $3.0-5.6B on rising revenues. Operating margins stayed in the mid-teens (~14-17%), reflecting improving operating leverage as volumes grow. Cash flow from operations was positive in each period (approx. $1.0-3.0B per quarter), with investing cash outflows offset by financing activity and net cash flow turning positive in several quarters. 🛡️ Balance Sheet & Liquidity Equity attributable to parent ranges around $58-64B with total assets near $69-79B. Current assets about $19-28B and current liabilities around $7-10B yield a healthy liquidity cushion. Debt levels remain modest relative to equity, supporting resilience. ⚠️ Key Drivers & Risks Drivers: AI/Data Center GPU demand; AMD product cadence and process technology advantages. Risks: Semiconductor cyclicality and valuation sensitivity to growth trajectories; competitive pressure in a consolidating GPU/CPU market.

A Analysis

AMD Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from roughly $7.44B to about $10.25B, a sustained upshift with a brief mid-period pause. Net Income climbed from about $0.264B to $1.383B, with quarterly oscillations but a clear uptrend (peaks in 2025 Q4 and 2026 Q1).

💰 Margins & Cash Flow

Gross margins held near 50-54%, with quarterly gross profit around $3.0-5.6B on rising revenues. Operating margins stayed in the mid-teens (~14-17%), reflecting improving operating leverage as volumes grow. Cash flow from operations was positive in each period (approx. $1.0-3.0B per quarter), with investing cash outflows offset by financing activity and net cash flow turning positive in several quarters.

🛡️ Balance Sheet & Liquidity

Equity attributable to parent ranges around $58-64B with total assets near $69-79B. Current assets about $19-28B and current liabilities around $7-10B yield a healthy liquidity cushion. Debt levels remain modest relative to equity, supporting resilience.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center GPU demand; AMD product cadence and process technology advantages.
Risks: Semiconductor cyclicality and valuation sensitivity to growth trajectories; competitive pressure in a consolidating GPU/CPU market.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"